Skip to main content
Top
Published in: Journal of Interventional Cardiac Electrophysiology 2/2017

01-08-2017

Health care utilization among adenosine-sensitive supraventricular tachycardia patients presenting to the emergency department

Authors: Thomas A. Dewland, Adam Oesterle, John Stein, Gregory M. Marcus

Published in: Journal of Interventional Cardiac Electrophysiology | Issue 2/2017

Login to get access

Abstract

Purpose

Although adenosine-sensitive supraventricular tachycardia (SVT) is generally curable, it remains an important cause of healthcare utilization. We sought to determine predictors of health care utilization among SVT patients presenting to the emergency department (ED).

Methods

We studied consecutive patients evaluated in an urban, academic ED for adenosine-sensitive SVT. The primary study outcomes were (1) ambulance transportation to the index ED visit, (2) hospital admission from the index ED encounter, and (3) recurrent SVT-associated ED encounters.

Results

Among 100 patients with adenosine-sensitive SVT, 35 were transported to the ED by ambulance. Prior electrophysiologist evaluation was associated with a significant 87% reduced odds of ambulance utilization (OR 0.13, 95% CI 0.03–0.67, p = 0.015). A total of 62 patients were subsequently admitted to the hospital. All patients with coronary artery disease, diabetes, syncope, and wide complex SVT were admitted. Similarly, individuals with an elevated troponin had a significantly greater odds of hospital admission (OR 16.8, 95% CI 1.9–148.4, p = 0.011). After the index ED visit, 60 patients were seen by an electrophysiologist, and 47 underwent catheter ablation. Individuals treated with catheter ablation had a significant 75% reduction in the risk of a recurrent ED visit for SVT (HR 0.25, 95% CI 0.10–0.62, p = 0.003).

Conclusions

Readily modifiable clinical factors, including a previous visit to an electrophysiologist and treatment with catheter ablation, are associated with reduced health care utilization among patients presenting to the ED with SVT.
Literature
1.
go back to reference Orejarena LA, Vidaillet H, DeStefano F, Nordstrom DL, Vierkant RA, Smith PN, et al. Paroxysmal supraventricular tachycardia in the general population. J Am Coll Cardiol. 1998;31(1):150–7.CrossRefPubMed Orejarena LA, Vidaillet H, DeStefano F, Nordstrom DL, Vierkant RA, Smith PN, et al. Paroxysmal supraventricular tachycardia in the general population. J Am Coll Cardiol. 1998;31(1):150–7.CrossRefPubMed
2.
go back to reference Murman DH, McDonald AJ, Pelletier AJ, Camargo CA. U.S. emergency department visits for supraventricular tachycardia, 1993–2003. Acad Emerg Med Off J Soc Acad Emerg Med. 2007;14(6):578–81. Murman DH, McDonald AJ, Pelletier AJ, Camargo CA. U.S. emergency department visits for supraventricular tachycardia, 1993–2003. Acad Emerg Med Off J Soc Acad Emerg Med. 2007;14(6):578–81.
3.
go back to reference Page, R. L., Joglar, J. A., Caldwell, M. A., Calkins, H., Conti, J. B., Deal, B. J., et al. (2015). 2015 ACC/AHA/HRS guideline for the management of adult patients with supraventricular tachycardia: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Journal of the American College of Cardiology. Page, R. L., Joglar, J. A., Caldwell, M. A., Calkins, H., Conti, J. B., Deal, B. J., et al. (2015). 2015 ACC/AHA/HRS guideline for the management of adult patients with supraventricular tachycardia: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Journal of the American College of Cardiology.
5.
go back to reference Rankin AC, Brooks R, Ruskin JN, McGovern BA. Adenosine and the treatment of supraventricular tachycardia. Am J Med. 1992;92(6):655–64.CrossRefPubMed Rankin AC, Brooks R, Ruskin JN, McGovern BA. Adenosine and the treatment of supraventricular tachycardia. Am J Med. 1992;92(6):655–64.CrossRefPubMed
6.
go back to reference Alboni P, Tomasi C, Menozzi C, Bottoni N, Paparella N, Fucà G, et al. Efficacy and safety of out-of-hospital self-administered single-dose oral drug treatment in the management of infrequent, well-tolerated paroxysmal supraventricular tachycardia. J Am Coll Cardiol. 2001;37(2):548–53.CrossRefPubMed Alboni P, Tomasi C, Menozzi C, Bottoni N, Paparella N, Fucà G, et al. Efficacy and safety of out-of-hospital self-administered single-dose oral drug treatment in the management of infrequent, well-tolerated paroxysmal supraventricular tachycardia. J Am Coll Cardiol. 2001;37(2):548–53.CrossRefPubMed
7.
go back to reference Tendera M, Wnuk-Wojnar AM, Kulakowski P, Malolepszy J, Kozlowski JW, Krzeminska-Pakula M, et al. Efficacy and safety of dofetilide in the prevention of symptomatic episodes of paroxysmal supraventricular tachycardia: a 6-month double-blind comparison with propafenone and placebo. Am Heart J. 2001;142(1):93–8.CrossRefPubMed Tendera M, Wnuk-Wojnar AM, Kulakowski P, Malolepszy J, Kozlowski JW, Krzeminska-Pakula M, et al. Efficacy and safety of dofetilide in the prevention of symptomatic episodes of paroxysmal supraventricular tachycardia: a 6-month double-blind comparison with propafenone and placebo. Am Heart J. 2001;142(1):93–8.CrossRefPubMed
8.
go back to reference Mauritson DR, Winniford MD, Walker WS, Rude RE, Cary JR, Hillis LD. Oral verapamil for paroxysmal supraventricular tachycardia: a long-term, double-blind randomized trial. Ann Intern Med. 1982;96(4):409–12.CrossRefPubMed Mauritson DR, Winniford MD, Walker WS, Rude RE, Cary JR, Hillis LD. Oral verapamil for paroxysmal supraventricular tachycardia: a long-term, double-blind randomized trial. Ann Intern Med. 1982;96(4):409–12.CrossRefPubMed
9.
go back to reference Winniford MD, Fulton KL, Hillis LD. Long-term therapy of paroxysmal supraventricular tachycardia: a randomized, double-blind comparison of digoxin, propranolol and verapamil. Am J Cardiol. 1984;54(8):1138–9.CrossRefPubMed Winniford MD, Fulton KL, Hillis LD. Long-term therapy of paroxysmal supraventricular tachycardia: a randomized, double-blind comparison of digoxin, propranolol and verapamil. Am J Cardiol. 1984;54(8):1138–9.CrossRefPubMed
10.
go back to reference Anderson JL, Platt ML, Guarnieri T, Fox TL, Maser MJ, Pritchett EL. Flecainide acetate for paroxysmal supraventricular tachyarrhythmias. The Flecainide Supraventricular Tachycardia Study Group. Am J Cardiol. 1994;74(6):578–84.CrossRefPubMed Anderson JL, Platt ML, Guarnieri T, Fox TL, Maser MJ, Pritchett EL. Flecainide acetate for paroxysmal supraventricular tachyarrhythmias. The Flecainide Supraventricular Tachycardia Study Group. Am J Cardiol. 1994;74(6):578–84.CrossRefPubMed
11.
go back to reference Pritchett EL, McCarthy EA, Wilkinson WE. Propafenone treatment of symptomatic paroxysmal supraventricular arrhythmias. A randomized, placebo-controlled, crossover trial in patients tolerating oral therapy. Ann Intern Med. 1991;114(7):539–44.CrossRefPubMed Pritchett EL, McCarthy EA, Wilkinson WE. Propafenone treatment of symptomatic paroxysmal supraventricular arrhythmias. A randomized, placebo-controlled, crossover trial in patients tolerating oral therapy. Ann Intern Med. 1991;114(7):539–44.CrossRefPubMed
12.
go back to reference Wanless RS, Anderson K, Joy M, Joseph SP. Multicenter comparative study of the efficacy and safety of sotalol in the prophylactic treatment of patients with paroxysmal supraventricular tachyarrhythmias. Am Heart J. 1997;133(4):441–6.CrossRefPubMed Wanless RS, Anderson K, Joy M, Joseph SP. Multicenter comparative study of the efficacy and safety of sotalol in the prophylactic treatment of patients with paroxysmal supraventricular tachyarrhythmias. Am Heart J. 1997;133(4):441–6.CrossRefPubMed
13.
go back to reference Henthorn RW, Waldo AL, Anderson JL, Gilbert EM, Alpert BL, Bhandari AK, et al. Flecainide acetate prevents recurrence of symptomatic paroxysmal supraventricular tachycardia. The Flecainide Supraventricular Tachycardia Study Group. Circulation. 1991;83(1):119–25.CrossRefPubMed Henthorn RW, Waldo AL, Anderson JL, Gilbert EM, Alpert BL, Bhandari AK, et al. Flecainide acetate prevents recurrence of symptomatic paroxysmal supraventricular tachycardia. The Flecainide Supraventricular Tachycardia Study Group. Circulation. 1991;83(1):119–25.CrossRefPubMed
14.
go back to reference Cockrell JL, Scheinman MM, Titus C, Helmy I, Langberg JJ, Lee MA, et al. Safety and efficacy of oral flecainide therapy in patients with atrioventricular re-entrant tachycardia. Ann Intern Med. 1991;114(3):189–94.CrossRefPubMed Cockrell JL, Scheinman MM, Titus C, Helmy I, Langberg JJ, Lee MA, et al. Safety and efficacy of oral flecainide therapy in patients with atrioventricular re-entrant tachycardia. Ann Intern Med. 1991;114(3):189–94.CrossRefPubMed
15.
go back to reference A randomized, placebo-controlled trial of propafenone in the prophylaxis of paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation. UK Propafenone PSVT Study Group. (1995). Circulation, 92(9), 2550–2557. A randomized, placebo-controlled trial of propafenone in the prophylaxis of paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation. UK Propafenone PSVT Study Group. (1995). Circulation, 92(9), 2550–2557.
16.
go back to reference Benditt DG, Dunnigan A, Buetikofer J, Milstein S. Flecainide acetate for long-term prevention of paroxysmal supraventricular tachyarrhythmias. Circulation. 1991;83(1):345–9.CrossRefPubMed Benditt DG, Dunnigan A, Buetikofer J, Milstein S. Flecainide acetate for long-term prevention of paroxysmal supraventricular tachyarrhythmias. Circulation. 1991;83(1):345–9.CrossRefPubMed
17.
go back to reference Bathina MN, Mickelsen S, Brooks C, Jaramillo J, Hepton T, Kusumoto FM. Radiofrequency catheter ablation versus medical therapy for initial treatment of supraventricular tachycardia and its impact on quality of life and healthcare costs. Am J Cardiol. 1998;82(5):589–93.CrossRefPubMed Bathina MN, Mickelsen S, Brooks C, Jaramillo J, Hepton T, Kusumoto FM. Radiofrequency catheter ablation versus medical therapy for initial treatment of supraventricular tachycardia and its impact on quality of life and healthcare costs. Am J Cardiol. 1998;82(5):589–93.CrossRefPubMed
18.
go back to reference Goldberg AS, Bathina MN, Mickelsen S, Nawman R, West G, Kusumoto FM. Long-term outcomes on quality-of-life and health care costs in patients with supraventricular tachycardia (radiofrequency catheter ablation versus medical therapy). Am J Cardiol. 2002;89(9):1120–3.CrossRefPubMed Goldberg AS, Bathina MN, Mickelsen S, Nawman R, West G, Kusumoto FM. Long-term outcomes on quality-of-life and health care costs in patients with supraventricular tachycardia (radiofrequency catheter ablation versus medical therapy). Am J Cardiol. 2002;89(9):1120–3.CrossRefPubMed
19.
go back to reference Calkins H, Yong P, Miller JM, Olshansky B, Carlson M, Saul JP, et al. Catheter ablation of accessory pathways, atrioventricular nodal reentrant tachycardia, and the atrioventricular junction: final results of a prospective, multicenter clinical trial. The Atakr Multicenter Investigators Group. Circulation. 1999;99(2):262–70.CrossRefPubMed Calkins H, Yong P, Miller JM, Olshansky B, Carlson M, Saul JP, et al. Catheter ablation of accessory pathways, atrioventricular nodal reentrant tachycardia, and the atrioventricular junction: final results of a prospective, multicenter clinical trial. The Atakr Multicenter Investigators Group. Circulation. 1999;99(2):262–70.CrossRefPubMed
20.
go back to reference Bubien RS, Knotts-Dolson SM, Plumb VJ, Kay GN. Effect of radiofrequency catheter ablation on health-related quality of life and activities of daily living in patients with recurrent arrhythmias. Circulation. 1996;94(7):1585–91.CrossRefPubMed Bubien RS, Knotts-Dolson SM, Plumb VJ, Kay GN. Effect of radiofrequency catheter ablation on health-related quality of life and activities of daily living in patients with recurrent arrhythmias. Circulation. 1996;94(7):1585–91.CrossRefPubMed
21.
go back to reference Lau CP, Tai YT, Lee PW. The effects of radiofrequency ablation versus medical therapy on the quality-of-life and exercise capacity in patients with accessory pathway-mediated supraventricular tachycardia: a treatment comparison study. Pacing and clinical electrophysiology : PACE. 1995;18(3 Pt 1):424–32.CrossRefPubMed Lau CP, Tai YT, Lee PW. The effects of radiofrequency ablation versus medical therapy on the quality-of-life and exercise capacity in patients with accessory pathway-mediated supraventricular tachycardia: a treatment comparison study. Pacing and clinical electrophysiology : PACE. 1995;18(3 Pt 1):424–32.CrossRefPubMed
22.
go back to reference Farkowski MM, Pytkowski M, Maciag A, Golicki D, Kowalik I, Czech M, et al. Patient’s age rather than severity of the arrhythmia influences the cost of medical treatment of atrioventricular nodal or atrioventricular reciprocating tachycardia. Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing. 2016;47(2):197–202.CrossRef Farkowski MM, Pytkowski M, Maciag A, Golicki D, Kowalik I, Czech M, et al. Patient’s age rather than severity of the arrhythmia influences the cost of medical treatment of atrioventricular nodal or atrioventricular reciprocating tachycardia. Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing. 2016;47(2):197–202.CrossRef
23.
go back to reference Bukkapatnam RN, Robinson M, Turnipseed S, Tancredi D, Amsterdam E, Srivatsa UN. Relationship of myocardial ischemia and injury to coronary artery disease in patients with supraventricular tachycardia. Am J Cardiol. 2010;106(3):374–7.CrossRefPubMed Bukkapatnam RN, Robinson M, Turnipseed S, Tancredi D, Amsterdam E, Srivatsa UN. Relationship of myocardial ischemia and injury to coronary artery disease in patients with supraventricular tachycardia. Am J Cardiol. 2010;106(3):374–7.CrossRefPubMed
24.
go back to reference Carlberg DJ, Tsuchitani S, Barlotta KS, Brady WJ. Serum troponin testing in patients with paroxysmal supraventricular tachycardia: outcome after ED care. Am J Emerg Med. 2011;29(5):545–8.CrossRefPubMed Carlberg DJ, Tsuchitani S, Barlotta KS, Brady WJ. Serum troponin testing in patients with paroxysmal supraventricular tachycardia: outcome after ED care. Am J Emerg Med. 2011;29(5):545–8.CrossRefPubMed
Metadata
Title
Health care utilization among adenosine-sensitive supraventricular tachycardia patients presenting to the emergency department
Authors
Thomas A. Dewland
Adam Oesterle
John Stein
Gregory M. Marcus
Publication date
01-08-2017
Publisher
Springer US
Published in
Journal of Interventional Cardiac Electrophysiology / Issue 2/2017
Print ISSN: 1383-875X
Electronic ISSN: 1572-8595
DOI
https://doi.org/10.1007/s10840-017-0259-1

Other articles of this Issue 2/2017

Journal of Interventional Cardiac Electrophysiology 2/2017 Go to the issue